New Therapies for Macular Degeneration

The Persistent Unmet Need Driving AMD Research

Age-related macular degeneration (AMD) is the fourth leading cause of blindness globally and a major driver of irreversible central vision impairment in individuals over the age of 50. 1 The global prevalence of dry AMD alone is estimated at 266 million people worldwide, with geographic atrophy (GA), its most advanced form, affecting approximately 2 to 3 million people in the United States and Europe. 2 Wet AMD, driven by pathological choroidal neovascularization and dysregulated vascular endothelial growth factor (VEGF) signaling, is managed primarily through intravitreal anti-VEGF injections, yet current standard-of-care protocols typically require clinic visits every 4 to 8 weeks to maintain optimal outcomes. 3 That frequency creates substantial psychological, logistical, and caregiver burden, and real-world adherence rates fall well short of clinical trial benchmarks, contributing to preventable vision loss.

Four FDA-approved anti-VEGF agents currently anchor the wet AMD treatment standard: aflibercept (Eylea), ranibizumab (Lucentis), brolucizumab-dbll (Beovu), and faricimab-svoa (Vabysmo). 4 Vabysmo represents the most recent approval in this class, employing a bispecific mechanism that simultaneously binds angiopoietin-2 and VEGF-A, allowing some patients to extend dosing intervals. 5 Despite these advances, a substantial proportion of patients continue to experience vascular leakage and vision decline, which has catalyzed a broad wave of next-generation therapeutic development.

Gene Therapy Candidates Advancing Through Phase 3

AAV-based gene therapy has emerged as the most intensively pursued next-generation platform for neovascular AMD, with the core premise that a single administration can deliver sustained intraocular expression of anti-angiogenic proteins, potentially eliminating repeated injections. 6 Leading clinical candidates reviewed in peer-reviewed literature include RGX-314, ADVM-022 (ixo-vec), 4D-150, and NG101, each utilizing different AAV vectors and delivery routes. 7 Intravitreal ixoberogene soroparvovec (ixo-vec), developed by Adverum Biotechnologies in partnership with Lilly, completed screening for its pivotal Phase 3 ARTEMIS trial ahead of schedule in September 2025, with full enrollment of at least 284 treatment-naive and previously treated patients anticipated in Q4 2025 and topline data readout accelerated to Q1 2027. 8

4D Molecular Therapeutics (4DMT) simultaneously advanced its intravitreal candidate 4D-150, completing enrollment for the 4FRONT-2 global Phase 3 trial in June 2026, approximately four months ahead of initial projections and with over 500 patients enrolled. 9 Both 4FRONT-1 and 4FRONT-2 Phase 3 readouts are expected in 2027. Surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed by AbbVie and REGENXBIO, is being evaluated via suprachoroidal delivery, with REGENXBIO also initiating its Phase IIb/III NAAVIGATE trial in diabetic retinopathy as a parallel program. 10 A systematic review and meta-analysis published in the American Journal of Ophthalmology, covering prospective studies through February 2026, concluded that gene therapy in neovascular AMD is both clinically meaningful and safe, with primary outcomes including best-corrected visual acuity, central subfield thickness, and annualized injection rate as key measures. 11

Dry AMD and Geographic Atrophy: Complement Pathway Programs

Geographic atrophy represents one of the hardest therapeutic targets in ophthalmology. The FDA granted fast track designation in July 2025 to Sanofi's SAR446597, a one-time intravitreal gene therapy engineered to simultaneously target two components of the complement cascade: C1s in the classical pathway and factor Bb in the alternative pathway. 12 This dual-targeting approach is designed to deliver sustained complement suppression from a single administration, addressing the underlying pathophysiology rather than managing symptoms with repeated injections. Sanofi is also evaluating a second gene therapy, SAR402663, in a Phase 1/2 study (NCT06660667), expanding its complement-focused retinal portfolio.

Complement Therapeutics completed dosing for Cohort 1 in the Opti-GAIN Phase I/II clinical trial of CTx001, an investigational AAV gene therapy targeting multiple complement pathways simultaneously, with an Independent Data Monitoring Committee recommending dose escalation following safety review in May 2026. 13 On the small-molecule front, Aviceda Therapeutics reported Phase 2b SIGLEC results for AVD-104 in December 2025, showing that both dosing arms produced 31 to 38 percent less GA lesion growth than prior randomized placebo-controlled trials or natural history cohorts, and participants in the monthly treatment arm experienced an improved mean visual acuity of positive 0.6 letters over the study period. 14 Separately, Ocugen announced positive 12-month data from its Phase 2 ArMaDa trial of OCU410 (AAV5-RORA), a modifier gene therapy showing a 31 percent reduction in lesion growth in the optimal dose group compared to control and 27 percent slower ellipsoid zone loss. 15

Sustained-Release TKIs and Bispecific Antibodies Reduce Injection Burden

Tyrosine kinase inhibitors (TKIs) in sustained-release intravitreal formulations represent a mechanistically distinct approach to reducing treatment frequency. Unlike extracellular anti-VEGF antibodies, TKIs act intracellularly to block VEGF receptor signaling, and their integration into depot delivery systems aims to maintain therapeutic concentrations over extended intervals. 3 Ocular Therapeutix's AXPAXLI (OTX-TKI) is among the furthest advanced, with the company announcing FDA alignment on a New Drug Application to be submitted in Q4 2026, based on SOL-1 Week 52 efficacy and safety data. 16 A key secondary endpoint in the ongoing SOL-R trial will evaluate AXPAXLI superiority versus aflibercept (8mg) administered every six months at Week 96, with topline results expected in Q1 2028.

Merck's bispecific antibody MK-8748 (Tiespectus, EYE201), which directly activates Tie2 signaling while simultaneously inhibiting VEGF, entered its pivotal Phase 2b/3 MALBEC trial in April 2026 following encouraging results from the Phase 1/2a RIOJA study conducted across neovascular AMD, diabetic macular edema, and branch retinal vein occlusion. 17 The dual mechanism targets both aberrant vessel growth and vascular instability, differentiating it from single-pathway inhibitors. A second MALBEC study in neovascular AMD is also scheduled within 2026 as part of a broader late-phase development program.

Emerging Platforms: Optogenetics, RNA Delivery, and Novel Molecular Strategies

Beyond gene replacement and antibody-based therapies, several platform technologies are showing preclinical and early clinical promise. Optogenetics, which uses gene therapy vectors to introduce light-sensing proteins into surviving retinal cells that have lost photoreceptor function, has demonstrated early efficacy and safety signals in clinical trials for inherited retinal diseases. Experts note that these strategies could be adapted for advanced AMD, particularly geographic atrophy, where photoreceptor loss is a central feature. 18 StarryGene's XMVA09, an AAV-delivered bispecific antibody targeting both VEGF-A and angiopoietin-2, became the world's first such construct to enter Phase II clinical development in June 2026, also representing the first ophthalmic AAV product based on a non-natural capsid in China to reach this milestone. 19

At the preclinical level, researchers published findings in 2026 on a DNA nanoflower LYTAC system combining VEGF degradation via lysosome-targeted chimera units with verteporfin-loaded photodynamic therapy, demonstrating effective suppression of choroidal neovascularization in animal models without noticeable systemic side effects. 20 A separate 2026 study described retina-targeted siRNA delivery using exosome-liposome hybrid vesicles to suppress VEGF signaling, offering a potential non-viral delivery alternative. Researchers also identified erucamide, a naturally occurring lipid molecule, as a protective signal that declines during retinal degeneration; nanoparticle delivery of erucamide in preclinical models slowed tissue breakdown by preserving the neurovascular environment via the TMEM19 receptor on myeloid immune cells. 21

Pipeline Overview, Key Risks, and Clinical Considerations

The AMD pipeline is extensive. DelveInsight's 2026 assessment identified more than 70 companies working on over 80 dry AMD therapies across all developmental phases, reflecting the scale of unmet need in this disease area. 22 MingMed Biotechnology presented Phase II results at ARVO 2026 for QA102, an oral therapy targeting intermediate AMD, in a double-blind, randomized, placebo-controlled trial of 150 participants, marking one of the first oral systemic approaches to reach this stage in AMD. 23 The breadth of these programs illustrates that no single mechanism has yet demonstrated the ability to halt AMD comprehensively.

Patients and clinicians should weigh several important risk and eligibility factors when evaluating emerging therapies. AAV-based gene therapies carry risks including preexisting immunity to viral vectors, potential intraocular inflammation following administration, and the irreversibility of genomic or sustained protein expression modifications. 6 Most advanced programs enroll treatment-naive or carefully selected previously treated patients, and eligibility criteria vary significantly across trials. Complement inhibitor therapies approved for dry AMD, including pegcetacoplan, require indefinite intravitreal administration every one to two months, a burden comparable to anti-VEGF regimens. Real-world dropout rates with current GA therapies are significant, underlining the importance of treatment accessibility, patient support infrastructure, and long-term monitoring protocols for any new agent entering the clinic.

Sources

1. International Journal of Retina - ijretina.com
2. MarketScreener / Ocugen Inc. ArMaDa Clinical Trial Announcement - marketscreener.com
3. Ophthalmology 360 - ophthalmology360.com
4. FDA Drug Labels for Eylea, Lucentis, Beovu - accessdata.fda.gov
5. FDA Drug Label for Vabysmo (faricimab-svoa) - accessdata.fda.gov
6. Nature Gene Therapy / AAV-based gene therapies for neovascular AMD - nature.com
7. International Journal of Retina Scoping Review (Susantono & Victor, 2026) - ijretina.com
8. BioSpace / Adverum Biotechnologies ARTEMIS Phase 3 Announcement - biospace.com
9. GlobeNewswire / BioSpace - 4DMT 4FRONT-2 Enrollment Completion, June 2026 - globenewswire.com
10. MarketScreener / REGENXBIO NAAVIGATE Trial First Patient Dosed - marketscreener.com
11. American Journal of Ophthalmology - Gene Therapy for nAMD Meta-Analysis - ajo.com
12. Sanofi Press Release / MedEdge MEA - SAR446597 Fast Track Designation, July 2025 - sanofi.com
13. MarketScreener / Complement Therapeutics Opti-GAIN Phase I/II Announcement - marketscreener.com
14. Yahoo Finance / Aviceda Therapeutics SIGLEC Phase 2b Results - finance.yahoo.com
15. MarketScreener / Ocugen OCU410 ArMaDa Phase 2 12-Month Data - marketscreener.com
16. BioSpace / Ocular Therapeutix AXPAXLI NDA Investor Day, June 2026 - biospace.com
17. BioSpace / Morningstar - Merck MK-8748 MALBEC Trial Initiation, April 2026 - biospace.com
18. BrightFocus Foundation - Optogenetics and Macular Degeneration - brightfocus.org
19. PackGene Biotech / StarryGene XMVA09 Phase II Announcement, June 2026 - packgene.com
20. Advanced Science - DNA Nanoflower LYTACs for Wet AMD (2026) - doi.org
21. Neuroscience News - Erucamide Lipid Molecule and Retinal Degeneration, June 2026 - neurosciencenews.com
22. OpenPR / DelveInsight - Dry Age Macular Degeneration Pipeline 2026 - openpr.com
23. Third News / MingMed Biotechnology QA102 Phase II ARVO 2026 Results - third-news.com